Cambridge, Massachusetts, United States, November 2025 — Matthew Hawryluk has started a new position as Chief Business Officer at Prime Medicine, Inc., where he will help steer commercial strategy, strategic partnerships, and long-term value creation for one of the most innovative gene-editing companies in the world. With nearly two decades of leadership across biotech, business development, and life sciences strategy, he brings deep expertise that will support Prime Medicine’s next phase of growth.
Before joining Prime Medicine, Matthew Hawryluk most recently served as Chief Business Officer at Adventris Pharmaceuticals on a part-time basis, contributing to strategic growth initiatives and partnership development. In parallel, he held the role of Chief Business Officer at AIRNA, strengthening business operations and supporting the organization’s strategic roadmap. He also continues to serve on the Board of Directors at Predictive Oncology and OUROTECH (PEAR BIO).
Prior to these assignments, he spent over nine years at Gritstone bio, where he held several senior leadership roles including EVP, Chief Business Officer, Head of Legal, and Boston Site Head. During this period, he led landmark collaborations and high-value agreements with organizations such as BARDA, Gilead Sciences, bluebird bio (now 2seventy bio), Bill & Melinda Gates Foundation, and CEPI, securing multi-million and billion-dollar partnerships that significantly advanced Gritstone’s vaccine and immunotherapy programs.
Earlier, Matthew contributed more than four years to Foundation Medicine in progressive business development roles, culminating in his position as Vice President, Corporate and Business Development. He spearheaded partnerships with 18 pharmaceutical and biotech companies, expanded the companion diagnostics ecosystem, and built the alliance management function from the ground up.
In the foundational years of his career, he held strategic roles at Thermo Fisher Scientific (Athena Diagnostics), BlueTree Capital Group, UPMC, and Amgen, where he worked across business development, strategy, commercialization frameworks, and life sciences consulting. These assignments shaped his strong cross-functional expertise across biotech innovation, M&A evaluation, early-stage strategy, and product development trajectories.
Matthew Hawryluk holds an MBA from Carnegie Mellon University – Tepper School of Business, specializing in entrepreneurship, finance, marketing, strategy, and organizational behavior, and received multiple prestigious scholarships. He also earned a PhD in Cell Biology and Biochemistry from the University of Pittsburgh School of Medicine, giving him a strong scientific foundation that complements his commercial leadership career.
About Prime Medicine, Inc.
Prime Medicine was founded to bring the promise of gene editing to patients through Prime Editing, a next-generation, “search-and-replace” genetic correction technology that can precisely restore normal DNA function. This breakthrough platform has the potential to address more than 90% of known disease-causing genetic mutations.
The company envisions a world where Prime Editing cures, halts, or prevents genetic diseases entirely. To realize this mission, Prime Medicine is building a team of exceptional scientific and business leaders committed to transforming the future of medicine and delivering lasting benefit to patients across the globe.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
